|
Clinical outcomes (n, %)
|
Univariate multivariate
|
|---|
|
HR (95% CI)
|
P
|
HR (95% CI)
|
P
|
|---|
|
MACE
|
1.190 (0.976–1.451)
|
0.085
|
1.145 (0.937–1.401)
|
0.186
|
|
All-cause death
|
1.477 (0.827–2.637)
|
0.188
|
1.268 (0.686–2.344)
|
0.449
|
|
Cardiac death
|
0.886 (0.363–2.159)
|
0.790
|
0.772 (0.293–2.039)
|
0.602
|
|
Non-fatal MI
|
0.834 (0.493–1.413)
|
0.50
|
0.758 (0.441–1.304)
|
0.317
|
|
Stent thrombosis
|
0.692 (0.289–1.654)
|
0.407
|
0.573 (0.222–1.480)
|
0.250
|
|
Revascularization
|
1.188 (0.936–1.508)
|
0.157
|
1.184 (0.931–1.505)
|
0.168
|
|
TVR
|
1.619 (1.193–2.198)
|
0.002
|
1.539 (1.128–2.099)
|
0.007
|
|
TLR
|
2.109 (1.501–2.963)
|
< 0.001
|
1.963 (1.390–2.772)
|
< 0.001
|
|
Stroke
|
1.087 (0.611–1.932)
|
0.778
|
0.976 (0.538–1.771)
|
0.936
|
|
Bleeding
|
1.022 (0.798–1.310)
|
0.861
|
1.055 (0.807–1.379)
|
0.696
|
|
BRAC 2_5
|
0.927 (0.625–1.374)
|
0.705
|
0.929 (0.625–1.381)
|
0.714
|
|
BRAC 3_5
|
0.613 (0.213–1.766)
|
0.364
|
0.630 (0.216–1.839)
|
0.397
|
- DM diabetes mellitus, G2-DES second generation drug-eluting stent, BP-DES biodegradable polymer drug-eluting stent, MACE major adverse cardiac events, MI myocardial infarction, TVR target vessel revascularization, BARC Bleeding Academic Research Consortium definition
